Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • Practice Current
  • Practice Buzz

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Clinical Practice
Home
A peer-reviewed clinical neurology journal for the practicing neurologist
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • Practice Current
  • Practice Buzz

Share

October 2013; 3 (5) Statistics in Clinical Practice

Cost-effectiveness analyses

Beauty and the beast?

Gary R. Cutter, Guoqiao Wang
First published October 14, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e3182a99280
Gary R. Cutter
Department of Biostatistics, UAB School of Public Health, Birmingham, AL.
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guoqiao Wang
Department of Biostatistics, UAB School of Public Health, Birmingham, AL.
MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Cost-effectiveness analyses
Beauty and the beast?
Gary R. Cutter, Guoqiao Wang
Neurol Clin Pract Oct 2013, 3 (5) 436-439; DOI: 10.1212/CPJ.0b013e3182a99280

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
153

Share

  • Article
  • Info & Disclosures
Loading

Article Information

vol. 3 no. 5 436-439
DOI: 
https://doi.org/10.1212/CPJ.0b013e3182a99280

Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published October 14, 2013.

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Gary R. Cutter, PhD and
    2. Guoqiao Wang, MS
  1. Gary R. Cutter, PhD and
  2. Scientific Advisory Boards:
    1. Participation of Data and Safety Monitoring Committees: Apotek; Biogen-Idec; Cleveland Clinic; Glaxo Smith Klein Pharmaceuticals; Gilead Pharmaceuticals; Modigenetech/Prolor; Merck/Ono Pharmaceuticals; Merck; Neuren; PCT Bio; Revalesio; Sanofi-Aventis; Teva; Vivus; NHLBI (Protocol Review Committee); NINDS; NMSS; NICHD (OPRU oversight committee);

    Gifts:
    1. NONE

    Funding for travel or speaker honoraria:
    1. (1) Consortium of MS Centers, speaker honoraria; (2) Bayer, speaker honoraria (3) Teva, Speaker honoraria

    Editorial Boards:
    1. (1) Multiple Sclerosis, Editorial Board, 2010-present (2) JASN, 2013- present, statistical consultant

    Patents:
    1. NONE

    Publishing Royalties:
    1. NONE

    Employment, Commercial Entity:
    1. NONE

    Consultancies:
    1. Consulting, Speaking fees & Advisory Boards: Alexion; Allozyne; Bayer; Celgene; Coronado Biosciences; Consortium of MS Centers (grant); Diogenix; Klein-Buendel Incorporated; Medimmune; Novartis; Nuron Biotech; Receptos; Spiniflex Pharmaceuticals; Teva pharmaceuticals

    Speakers' Bureaus:
    1. NONE

    Other activities:
    1. (1) NINDS Grant with Multiple Sclerosis as the patient population (2) NARCOMS MS Patient Registry

    Clinical Procedures or Imaging Studies:
    1. NONE

    Research Support, Commercial Entities:
    1. No direct grants, but work on studies funded to the Consortium of MS Centers subcontracted for analysis of NARCOMS Registry.

    Research Support, Government Entities:
    1. U01 NS 042685 (Cutter) 09/23/2005 – 08/31/2015 NIH/NINDS Thymectomy Plus Prednisone vs. Prednisone Alone in NonThymomatous Myasthenia Gravis This multinational clinical trial aims to assess the utility of thymectomy in treating nonthymomatous Myasthenia Gravis patients comparing surgery plus medications versus medications alone. U01 NS 45719 (Lublin) 09/30/2003 – 11/30/2013 NIH/NINDS A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis. The purpose of this project is to assess the impact of combination therapy in the treatment of RRMS. P30 DK 079337 (Agarwal) 09/01/2008 – 07/31/2013 NIH/NIDDK UAB/UCSD O’Brien Core Center for Acute Kidney Injury Research The major objective of this grant is to provide state-of-the-art core resources to address experimental questions for the advancement of AKI research P30-AI 027767 (Saag) 03/01/2009 – 02/28/2014 NIH/NIAID UAB Center for Aids Research is organized as a partnership between the University of Alabama at Birmingham and the Southern Research Institute. The primary purpose of this partnership is to generate interdisciplinary AIDS research efforts. This Center is responsible for planning, evaluating, managing and documenting a broad array of research activities within two institutions. Particular emphasis is placed upon linking clinical and basic science through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs. No number assigned (Mark) 10/01/2009 – 09/30/2013 National Multiple Sclerosis Society Rehabilitating Extremity Use after Multiple Sclerosis This project compares CI therapy and complementary and alternative medicine treatments to determine their changes in the extent of more-affected arm use in the life setting and maximal movement ability in the laboratory for individuals with multiple sclerosis. R01 HD 064729 (Tita) 04/01/2010 – 03/31/2014 NIH/NICHD Caesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) Trial A multicenter randomized trial to determine the efficacy and safety of a modified (extended-spectrum) antibiotic prophylaxis strategy at cesarean delivery to reduce surgical site infections. UL1 RR 02577 (Kimberly) 05/19/2008 – 04/30/2013 NIH/NCRR UAB Center for Clinical & Translational Science (CCTS) The major goal of this Medicare United with Simple Clinical trials Expanded network (MUSCLE) is to conduct comparative effectiveness research by developing a “network of networks” for conducting pragmatic trials of therapeutics for chronic musculoskeletal diseases. R01 AG 021927 (Marson) 07/01/2010 – 06/30/2015 NIH/NIA Functional Change in Mild Cognitive Impairment (COINS) This R01 project investigates longitudinal change in higher order functional abilities in patients with MCI, and develops predictor models for clinical progression and conversion from MCI to dementia. U01 HL 102235 (Kinsella/Cutter) 09/07/2010 – 06/30/2013 NIH/NHLBI Phase II Trial of Sildenafil in Newborns with Persistent Pulmonary Hypertension This Phase II, multi-center, randomized, double-blind, placebo-controlled trial pursues the hypothesis that IV sildenafil will acutely reduce pulmonary artery pressure and improve oxygenation in near-term and term infants with PPHN, thus reducing the need for rescue therapy iNO and/or ECMO. P30 DK 074038 (Yoder) 09/30/2010 – 06/30/2015 NIH/NIDDK Hepato/Renal Fibrocystic Diseases Core Center. The University of Alabama at Birmingham Recessive Polycystic Kidney Disease Core Center (UAB RPKDCC) has established a NIDDK-funded, interdisciplinary center of excellence in PKD-related research, with specific emphasis on recessive PKD. Among the five Cores, the UAB RPKDCC includes the ARPKD Clinical and Genetic Resource, a Core resource designed to develop a unique set of clinical, genetic, and educational resources for ARPKD. The Core has three primary objectives: (1) to extend the observational study of ARPKD initiated by the North American ARPKD Database; (2) to provide a mechanism for genetic evaluation of patients with both classic ARPKD and unusual phenotypes of recessive PKD; and (3) to develop educational tools for physicians and patients regarding the natural history, cause, development and effects of the disease, genetic testing, and clinical trials applicable to ARPKD. R01 AG 037561 (Schneider) 04/01/2011 – 03/31/2014 NIH/NIA Synthesis of Longer-Term Alzheimer Disease Studies in Order to Model and Improve Clinical Trials Methods and Outcomes: Alzheimer Disease Clinical The results of this research will have a broad and lasting impact on trial designs for Alzheimer disease, mild cognitive impairment, and neurodegenerative disorders, and trials in which cognitive improvement is a targeted outcome. It will address important issues in the assumptions underlying the design decisions. This will lead to better understanding and improvement in the methods for future clinical trials and improve the likelihood for identifying effective treatments, as well as identifying ineffective treatments earlier in development. No number assigned (Cutter) 01/01/2004 – 12/31/2012 Consortium of MS Centers (CMSC) North American Research Consortium on Multiple Sclerosis (NARCOMS) The goals of this project are to facilitate a confidential way for patients to supply valuable information to researchers about their course of disease that may lead to more effective treatments and care for people living with MS, while reducing the time and cost of conducting studies; provide a worldwide research resource for people living with multiple sclerosis so they can provide information about themselves and their course of disease; and develop new collaborations between researchers, patients, and healthcare providers. UAB provides programming and analytic support for the NARCOMS registry. BAA-NIAID-DMID-NIHAI2010101 (Gnann/Kimberlin) 10/01/2011 – 09/30/2016 NIH/NIAID These contracts are to accomplish coordinating of various clinical trials with titles listed below: Safety Tolerability and Pharmacokinetics of CMX-001 in Renal Transplant Recipients with BKV Viremia: A Phase IIA Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study A Pharmacokinetic/Pharmacodynamic and Resistance Evaluation of Intravenous Ganciclovir in Premature Infants Adaptive Sequential Study Evaluating Prevention of Neonatal HSV: Detection of Maternal Shedding at Delivery Followed by Preemptive Antiviral Therapy in Exposed Neonates A Phase II 6 Weeks Oral Valganciclovir versus Placebo in Infants with Congenital CMV Infection and Hearing Loss 1U34AR062891-01 (Saag) 04/01/2012 – 03/31/2014 NIH/NIAMS Planning Grant for the Active ComparaTor Osteoporosis Large Simple Trial (ATLAST) The overall goals of this project are to collaborate with an advisory group of national osteoporosis, clinical trial, and community research experts to: (1) finalize the study protocol with respect to the study population, recruitment plan, primary and secondary outcomes, data collection/analysis plan; (2) develop a manual of procedures; and (3) develop effective linkages to Medicare data for long-term surveillance of participants.

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. (1) Consortium of MS Centers (2) Myasthenia Gravis Foundation of America, grant for MG Registry

    Stock/Stock Options/Board of Directors Compensation:
    1. Pythagoras, Inc. Sub S Corporation - President.

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. NONE

  3. Guoqiao Wang, MS
  4. Scientific Advisory Boards:
    1. NONE

    Gifts:
    1. NONE

    Funding for Travel or Speaker Honoraria:
    1. NONE

    Editorial Boards:
    1. NONE

    Patents:
    1. NONE

    Publishing Royalties:
    1. NONE

    Employment, Commercial Entity:
    1. NONE

    Consultancies:
    1. NONE

    Speakers' Bureaus:
    1. NONE

    Other Activities:
    1. NONE

    Clinical Procedures or Imaging Studies:
    1. NONE

    Research Support, Commercial Entities:
    1. NONE

    Research Support, Government Entities:
    1. NONE

    Research Support, Academic Entities:
    1. NONE

    Research Support, Foundations and Societies:
    1. NONE

    Stock/Stock Options/Board of Directors Compensation:
    1. NONE

    License Fee Payments, Technology or Inventions:
    1. NONE

    Royalty Payments, Technology or Inventions:
    1. NONE

    Stock/Stock Options, Research Sponsor:
    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:
    1. NONE

    Legal Proceedings:
    1. NONE

  1. Department of Biostatistics, UAB School of Public Health, Birmingham, AL.
  1. Correspondence to:
    cutterg{at}uab.edu
View Full Text

Article usage

Article usage: October 2013 to August 2023

AbstractFullPdfSource
Oct 20131131327Highwire
Nov 20135727Highwire
Dec 20135216Highwire
Jan 20143603Highwire
Feb 20143102Highwire
Mar 20142904Highwire
Apr 20142202Highwire
May 20141631Highwire
Jun 20141201Highwire
Jul 20141110Highwire
Aug 20141111Highwire
Sep 20141700Highwire
Oct 2014800Highwire
Nov 2014900Highwire
Dec 20141200Highwire
Jan 2015300Highwire
Jan 2015032pmc
Feb 2015800Highwire
Feb 2015041pmc
Mar 20152004Highwire
Mar 2015062pmc
Apr 2015403Highwire
Apr 2015022pmc
May 20151101Highwire
May 2015053pmc
Jun 20151900Highwire
Jun 2015012pmc
Jul 20151800Highwire
Jul 2015020pmc
Aug 2015410Highwire
Aug 2015030pmc
Sep 2015300Highwire
Sep 2015053pmc
Oct 2015711Highwire
Oct 2015071pmc
Nov 20151703Highwire
Nov 2015011pmc
Dec 20151000Highwire
Dec 2015031pmc
Jan 20161100Highwire
Jan 2016030pmc
Feb 20161100Highwire
Feb 2016051pmc
Mar 20161100Highwire
Mar 2016040pmc
Apr 2016600Highwire
Apr 2016031pmc
May 20161900Highwire
May 2016051pmc
Jun 20161502Highwire
Jun 2016041pmc
Jul 20161400Highwire
Jul 2016031pmc
Aug 20161500Highwire
Aug 2016042pmc
Sep 20162400Highwire
Sep 2016081pmc
Oct 20161100Highwire
Oct 2016031pmc
Nov 20163900Highwire
Nov 2016020pmc
Dec 20162200Highwire
Dec 2016010pmc
Jan 20172700Highwire
Jan 2017040pmc
Feb 20171601Highwire
Feb 2017081pmc
Mar 20171600Highwire
Mar 2017090pmc
Apr 20172000Highwire
Apr 2017134pmc
May 20172700Highwire
May 2017155pmc
Jun 20171700Highwire
Jul 20171100Highwire
Jul 20170810pmc
Aug 20171400Highwire
Aug 2017066pmc
Sep 2017800Highwire
Sep 2017022pmc
Oct 20171501Highwire
Oct 2017022pmc
Nov 20171000Highwire
Nov 2017034pmc
Dec 2017600Highwire
Jan 20181100Highwire
Feb 20181200Highwire
Mar 2018700Highwire
Apr 2018800Highwire
Apr 2018022pmc
May 2018501Highwire
Jun 2018711Highwire
Jun 2018045pmc
Jul 20181900Highwire
Aug 2018700Highwire
Aug 2018022pmc
Sep 20181000Highwire
Oct 2018711Highwire
Nov 2018500Highwire
Dec 20181200Highwire
Jan 2019900Highwire
Feb 2019800Highwire
Mar 20191301Highwire
Apr 20191000Highwire
May 20191100Highwire
Jun 20191100Highwire
Jul 20192200Highwire
Sep 20191201Highwire
Oct 20191711Highwire
Nov 20191400Highwire
Dec 2019900Highwire
Jan 2020900Highwire
Feb 2020800Highwire
Mar 2020500Highwire
Apr 2020400Highwire
May 20201613Highwire
Jun 2020500Highwire
Jul 2020500Highwire
Aug 20201000Highwire
Sep 2020700Highwire
Oct 20201700Highwire
Nov 20202000Highwire
Dec 20201810Highwire
Jan 2021710Highwire
Feb 20211300Highwire
Mar 20211000Highwire
Apr 2021600Highwire
May 2021700Highwire
Jun 2021800Highwire
Jul 20211200Highwire
Aug 20212311Highwire
Sep 20211000Highwire
Oct 20211700Highwire
Nov 2021600Highwire
Dec 20211200Highwire
Jan 2022800Highwire
Feb 20221100Highwire
Mar 20221500Highwire
Apr 20221911Highwire
May 2022900Highwire
Jun 2022610Highwire
Jul 2022712Highwire
Aug 2022500Highwire
Sep 20221600Highwire
Oct 20221100Highwire
Nov 20223600Highwire
Dec 20221200Highwire
Jan 20231900Highwire
Feb 2023900Highwire
Mar 2023400Highwire
Apr 2023100Highwire
May 2023800Highwire
Jun 2023210Highwire
Jul 2023300Highwire
Aug 2023400Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • STUDY FUNDING
    • DISCLOSURES
    • Footnotes
    • REFERENCES
  • Info & Disclosures
Advertisement

Association Between Fluctuations in Blood Lipid Levels Over Time With Incident Alzheimer Disease and Alzheimer Disease–Related Dementias

Dr. Sevil Yaşar and Dr. Behnam Sabayan

► Watch

Related Articles

  • Cost-effectiveness dataAre neurologists in practice equipped to interpret them?
  • Reading a cost-effectiveness or decision analysis studyFive things to consider

Topics Discussed

  • All epidemiology
  • Clinical trials Methodology/study design
  • Clinical trials Systematic review/meta analysis
  • Clinical trials Observational study (Cohort, Case control)

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Views and Reviews
    The present efficacy of multiple sclerosis therapeutics
    Is the new 66% just the old 33%?
    Eric C. Klawiter, Anne H. Cross, Robert T. Naismith et al.
    Neurology, September 21, 2009
  • Article
    Risk of relapse after natalizumab withdrawal
    Results from the French TYSEDMUS cohort
    Caroline Papeix, Sandra Vukusic, Romain Casey et al.
    Neurology: Neuroimmunology & Neuroinflammation, October 28, 2016
  • Research
    Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
    Tim Spelman, Tomas Kalincik, Vilija Jokubaitis et al.
    Neurology: Clinical Practice, March 21, 2016
  • Article
    Initial high-efficacy disease-modifying therapy in multiple sclerosis
    A nationwide cohort study
    Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg et al.
    Neurology, July 07, 2020

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Clinical Practice |  Print ISSN: 2163-0402
Online ISSN: 2163-0933

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise